---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-124829"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2026-11-10T13:21:10+00:00"
generated_at: "2026-11-10T13:25:07.248441+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MaxCyte to acquire Akron Bio for $151.8M; Q3 revenue up 49% to $10.2M

## Summary
- Deal: $105M cash + 20,639,733 MXCT shares (~$26.8M) + $20M deferred ($10M each in Jan 2028 and Jan 2029); total $151.8M.
- Akron Bio expected 2026 revenue ~$28M and EBITDA $7-8M; products embedded in five approved therapies and >100 clinical programs.
- Q3 2026 revenue $10.2M (+49% YoY): core $8.2M (+27%), SPL $2.0M vs $0.4M; gross margin 83%; net loss $4.8M vs $12.4M.
- FY2026 revenue guidance raised to at least $34.5M (core ~$28M, SPL at least $6.5M); cash $132.7M at Sept 30.
- MidCap facility up to $75M; expects $22M drawn at close. Deal needs HSR and Nasdaq listing approval, no stockholder vote; targeted before end-2026.

## SEC filing metadata
- accession: 0001104659-26-124829
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2026-11-10T13:21:10+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000110465926124829/0001104659-26-124829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000110465926124829/tm2629420d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-124829
- JSON: https://secwatch.observer/filing/0001104659-26-124829.json
- Plain text: https://secwatch.observer/filing/0001104659-26-124829.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.